RT Journal Article
SR Electronic
T1 Renal function is preserved following Tenofovir Disoproxil Fumarate (TDF) initiation among Rwandan’s living with HIV
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20114249
DO 10.1101/2020.05.27.20114249
A1 Rwibasira, Gallican N.
A1 Kim, Hae-Young
A1 Twizere, Christella
A1 Hoover, Donald R
A1 Shi, Qiuhu
A1 Adedimeji, Adebola
A1 Ross, Jonathan
A1 Murenzi, Gad
A1 Sinayobye, Jean d’Amour
A1 Anastos, Kathryn
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.27.20114249.abstract
AB Background Tenofovir disoproxil fumarate (TDF) is the antiretroviral drug most commonly associated with renal dysfunction. However, few studies have examined this association in sub-Saharan Africa despite recent scale-up of antiretroviral therapy (ART) to all people living with HIV (Treat All) in this region. We assessed estimated glomerular filtration rate (eGFR) change among HIV infected Rwandan adults following first line TDF-based therapy initiation.Methods This prospective, observational study was conducted in 10 Rwandan health centers. Participants were ART-naive adults (≥18 years) living with HIV who initiated TDF-based ART from 1st July 2016 through 30th July 2018. The primary outcome was eGFR change from pre-(within 12 months) to post-TDF initiation (within 6 months).Results Of 476 patients with pre- and post-TDF eGFR measurements, 264 (55.5%) were women and mean age was 35.9 years (SD 9.6). Mean pre-TDF eGFR was 92.4 (SD 24.0) and mean post-TDF was 96.0 (SD 21.0) mL/min/1.73m2. Mean pre-to post-TDF change thus increased 3.60 (SD, 26.6) mL/min/1.73m2 (p=0.001).Conclusion We detected a statistically significant clinically small renal function improvement within 6 months following TDF initiation among 476 ART-naïve patients. This supports continued TDF use for first-line treatment.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a research article, not a clinical trialFunding StatementThere is no sternal funding to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Rwanda National Ethics Committee and the institutional review board of the Albert Einstein College of MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study are available on the data set of the Central Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) https://www.iedea.org